To read the full article, please login. The full content of this article and all premium articles is available exclusively for site members.
Site membership is free. If you are an existing user, please login. New users may register below.
Indian government forces Bayer to accept generic Nexavar competition – FiercePharma
India has invoked its compulsory licensing rules for the first time, allowing the domestic drugmaker Natco Pharma to make and sell a version of Bayer’s cancer drug Nexavar–despite the fact that Nexavar is still on patent. We think this is quite a significant development. What does it mean for ROI of big pharma companies R&D ? What does it mean for IP integrity for doing business in India ? Indian government forces Bayer to accept generic Nexavar competition – FiercePharma.